Table 3 Clinical characteristics and fasting serum long-acting natriuretic peptide levels of 98 congestive heart failure patients
Characteristic | Number (%) | LANP (ng/ml) | P value | |
|---|---|---|---|---|
Gender | Male | 46 (46.9) | 3.07 ± 2.59 | 0.589 |
Female | 52 (53.1) | 4.39 ± 5.53 | ||
Diabetes | No | 60 (61.2) | 3.32 ± 2.78 | 0.886 |
Yes | 38 (38.8) | 4.48 ± 6.21 | ||
Hypertension | No | 28 (28.6) | 5.04 ± 7.04 | 0.626 |
Yes | 70 (71.4) | 3.26 ± 2.76 | ||
Hyperlipidaemia | No | 32 (32.7) | 5.18 ± 6.59 | 0.376 |
Yes | 66 (67.3) | 3.09 ± 2.72 | ||
Metabolic syndrome | No | 52 (53.1) | 5.51 ± 5.44 | <0.001* |
|  | Yes | 46 (46.9) | 1.80 ± 1.09 |  |
Angiotensin-converting enzyme inhibitor use | No | 68 (69.4) | 3.58 ± 4.68 | 0.786 |
Yes | 30 (30.6) | 4.20 ± 3.84 | ||
Angiotensin receptor blocker use | No | 62 (63.3) | 4.17 ± 5.28 | 0.820 |
Yes | 36 (36.7) | 3.09 ± 2.22 | ||
β-blocker use | No | 46 (46.9) | 4.07 ± 5.78 | 0.548 |
Yes | 52 (53.1) | 3.51 ± 2.79 | ||
Calcium channel blocker use | No | 58 (59.2) | 4.49 ± 5.35 | 0.263 |
Yes | 40 (40.8) | 2.73 ± 2.26 | ||
Fibrate use | No | 94 (95.9) | 3.86 ± 4.48 | 0.511 |
Yes | 4 (4.1) | 1.66 ± 0.17 | ||
Statin use | No | 76 (77.6) | 3.82 ± 4.80 | 0.573 |
Yes | 22 (22.4) | 3.61 ± 2.86 | ||
Thiazide use | No | 48 (49.0) | 2.96 ± 2.54 | 0.548 |
Yes | 50 (51.0) | 4.55 ± 5.61 | ||
Sulfaurea use | No | 92 (93.9) | 3.81 ± 4.54 | 0.677 |
Yes | 6 (6.1) | 3.23 ± 1.57 | ||
Metformin use | No | 82 (83.7) | 3.44 ± 2.91 | 0.935 |
Yes | 16 (16.3) | 5.49 ± 9.01 | ||
Aspirin use | No | 56 (57.1) | 3.87 ± 5.28 | 0.585 |
Yes | 42 (42.9) | 3.64 ± 3.01 | ||
Clopidogrel use | No | 86 (87.8) | 3.80 ± 4.631 | 0.474 |
Yes | 12 (12.2) | 3.59 ± 2.59 | ||